ClinicalTrials.gg
RecruitingNCT06908525TYDQ-15Updated Nov 19, 2026

Norwegian Translation of The Things You Do Questionnaire 15-Item Version

An observational study in General Adult Population and Age 16 and Older, sponsored by Haukeland University Hospital. Recruiting at 1 site in Norway. Open to participants aged 16 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Haukeland University Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 19, 2026Now RecruitingFirst site in Norway+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
1,000
Ages
16 Years to 100 Years
Sex
All
01

Study summary

Psychotherapy aims to modify dysfunctional patterns of thinking, feeling, and behaving to improve mental health. A five-factor model of adaptive behaviors, operationalized in the Things You Do Questionnaire (TYDQ), has been identified as a mediator of treatment response in depression and anxiety interventions. The short-form TYDQ-15 is a key component of a transdiagnostic treatment promoting adaptive behavior. To implement this intervention in Norway, the TYDQ-15 requires translation and cultural adaptation, following established guidelines for clinical assessment instruments. Currently unavailable in Norwegian, its translation and psychometric evaluation are necessary for clinical application. This study aims to (1) produce a culturally adapted Norwegian version of the TYDQ-15 and (2) assess its psychometric properties, including reliability, factor structure, and criterion validity, within a Norwegian population. The findings will facilitate the integration of the Things You Do Intervention into Norwegian mental health services.

02

Conditions studied

  • General Adult Population
  • Age 16 and Older

Keywords

  • Translation
  • TYDQ-15
  • Psychometric Evaluation
03

In context

Lead sponsor

Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

General population of Norway

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 16 years
  • Native Norwegian speaker

Exclusion criteria

Exclusion Criteria:

  • Does not speak Norwegian fluently
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Things You Do Questionnaire 15-Item Version (TYDQ-15)

    The Things You Do Questionnaire - 15 Item Version (TYDQ-15) measures how frequently one engages in adaptive behavior with 15 items scored 0 ("never") to 4 ("every day"). The 15 items are grouped into the five domains of "meaningful activities", "healthy thinking", "goals and plans", "healthy routines", and "social connections. The original English language instrument has been shown to have acceptable psychometric properties across representative population samples.

    Time frame: Singe time point, at enrolment.

Secondary outcomes

  1. The Patient Health Questionnaire (PHQ-9)

    The Patient Health Questionnaire (PHQ-9) - measures depression severity with nine items scored 0 ("not at all") to 3 ("nearly every day"), corresponding to the criteria for major depression in the DSM-5. The sum of the nine items ranges from 0-27. The scale has demonstrated adequate psychometric properties across different samples and has been found to be sensitive to change in depressive symptoms.

    Time frame: Single time point, at enrolment.

  2. The Generalized Anxiety Disorder Scale (GAD-7)

    The Generalized Anxiety Disorder Scale (GAD-7) - measures anxiety severity with seven items scored 0 ("not at all") to 3 ("nearly every day") corresponding to symptoms of anxiety disorders. The sum score ranges from 0-21. GAD-7 has demonstrated adequate psychometric properties across different samples and has been found to be sensitive to the presence of anxiety disorders.

    Time frame: Single time point, at enrolment.

  3. The Satisfaction with Life Scale (SWLS)

    The Satisfaction with Life Scale (SWLS) - measures life-satisfaction with 5 items scored 1 ("strongly disagree") to 7 ("strongly agree"), corresponding to statements of general life satisfaction. Sum scores range from X to Y with higher scores indicating greater life satisfaction. The SWLS has demonstrated adequate psychometric properties across different samples.

    Time frame: Single time point, at enrolment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The sharing of IPD for this study will require guaranteed anonymity for all involved participants. Unless such anonymity can be guaranteed, IPD will not be shared outside the research team. Current advances in machine learning and AI introduce difficult questions regarding the possibility of re-identification of research participants from patterns in the data. Decisions of IPD publication therefore require additional consideration.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Mar 2025 → Sep 2025 and primary completion Apr 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 3, 2025
StartActual
Sep 8, 2025was Mar 2025
Primary completionEst.
Jan 2027was Apr 2026
CompletionEst.
Feb 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in Norway
Show site
  • Haukeland University Hospital · Bergen, Norway
Nov 19, 2026
Start date
Mar 24, 2025→Sep 8, 2025 (actual)
Nov 19, 2026
Primary completion
Apr 1, 2026→Jan 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Norway
    Show site
    • Haukeland University Hospital · Bergen, Norway
    Start date Mar 24, 2025→Sep 8, 2025 (now actual)
    Primary completion Apr 1, 2026→Jan 2027
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06908525
Responsible party
Aleksander Gulla Heltne (Principal Investigator, Haukeland University Hospital) — Principal investigator
First posted
Apr 3, 2025
Start date
Sep 8, 2025
Primary completion
Jan 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Aleksander G Heltne, PhD
Contact
aleksander.gulla.heltne@helse-bergen.no
00000000 ext. 0047

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion